Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
Sponsor: Novartis Pharmaceuticals
Summary
This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.
Official title: A Randomized, Placebo-controlled, Parallel Group, 72-week Study to Evaluate the Efficacy and Safety of VHB937 in Participants With Early Alzheimer's Disease Followed by an Extension
Key Details
Gender
All
Age Range
50 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
407
Start Date
2025-08-07
Completion Date
2030-12-31
Last Updated
2026-03-23
Healthy Volunteers
No
Conditions
Interventions
VHB937
VHB937 solution for infusion
VHB937
VHB937 solution for infusion
Placebo
Solution for infusion
Locations (52)
Banner Alzheimers Institute
Phoenix, Arizona, United States
University of California San Diego
La Jolla, California, United States
University of California at Los Angeles
Los Angeles, California, United States
Jem Research Institute
Atlantis, Florida, United States
Visionary Investigators Network
Aventura, Florida, United States
K2 Medical Research LLC
Maitland, Florida, United States
K2 Medical Research LLC
Maitland, Florida, United States
Renstar Medical Research
Ocala, Florida, United States
Charter Research The Villages
The Villages, Florida, United States
Alzheimers Research Treatment Ctr
Wellington, Florida, United States
Alzheimers Research Treatment Ctr
Wellington, Florida, United States
Conquest Research
Winter Park, Florida, United States
Hawaii Pacific Neuroscience LLC
Honolulu, Hawaii, United States
University of Kansas Hospital
Fairway, Kansas, United States
ActivMed Practices and Research
Methuen, Massachusetts, United States
Citizens Memorial Hospital Neurology CLinic
Bolivar, Missouri, United States
UNC Hosp Invest Drug Serv Pharm
Chapel Hill, North Carolina, United States
The Ohio State University
Columbus, Ohio, United States
Neural Net Research
Portland, Oregon, United States
Abington Neurological Associates Ltd
Willow Grove, Pennsylvania, United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
University of Washington Medical Center
Seattle, Washington, United States
Novartis Investigative Site
Camperdown, New South Wales, Australia
Novartis Investigative Site
Kogarah, New South Wales, Australia
Novartis Investigative Site
Box Hill, Victoria, Australia
Novartis Investigative Site
North York, Ontario, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Toulouse, Haute Garonne, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Itabashi Ku, Tokyo, Japan
Novartis Investigative Site
Kodaira, Tokyo, Japan
Novartis Investigative Site
Shinjuku Ku, Tokyo, Japan
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Bialystok, Poland
Novartis Investigative Site
Wroclaw, Poland
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Incheon, South Korea
Novartis Investigative Site
Incheon, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Mölndal, Sweden
Novartis Investigative Site
Stockholm, Sweden
Novartis Investigative Site
Aberdeen, United Kingdom
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
Southampton, United Kingdom